-
A115346-250mgSelective cAMP phosphodiesterase inhibitor. Positive inotropic agent.
-
A115346-50mgSelective cAMP phosphodiesterase inhibitor. Positive inotropic agent.
-
A274705-100mgStore at Room Temperature. The product can be stored for up to 12 months.
-
A274705-10mgStore at Room Temperature. The product can be stored for up to 12 months.
-
A274705-25mgStore at Room Temperature. The product can be stored for up to 12 months.
-
A126470-100mgAnastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
-
A126470-1gAnastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
-
A126470-25gAnastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
-
A126470-500mgAnastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
-
A126470-5gAnastrozole is known to inhibit the CYP19 enzyme (aromatase, IC50 = 15 nM) that converts androgens to estrogens. Anastrozole has been seen to reversibly bind to the CYP19 enzyme through competitive inhibition.
-
A126046-10mgApixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
-
A126046-1gApixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.